Growth in Launch Products
Launch products grew 5.3% at constant exchange rate (CER), representing over 50% of revenue. This growth is expected to accelerate in the second half of the fiscal year.
Strong Free Cash Flow
Adjusted free cash flow was JPY 525.4 billion, including improvements in working capital, indicating strong cash generation despite challenges.
Pipeline Advancements
Positive Phase III studies for rusfertide and oveporexton, with zasocitinib Phase III data expected by the end of the calendar year. The pipeline is further enriched by a strategic partnership with Innovent Biologics.
Innovent Biologics Partnership
The partnership with Innovent Biologics adds cutting-edge assets to Takeda's oncology pipeline, including PD-1/IL-2 alpha bias bispecific and next-generation ADCs.